Moderna's Comeback Is Finally Taking Shape -- and There May Be More Upside Ahead
Breaking news: Moderna isn't just a "pandemic stock" after all.
Overview
After several years of lagging the market due to a weakening coronavirus business, Moderna (NASDAQ: MRNA) is finally getting its mojo back. The company's shares are up 402% this year, as of writing, thanks to significant clinical and regulatory progress. Yet Moderna likely hasn't peaked and may see further gains as it continues to advance its mRNA vaccine platform.
Image source: Getty Images.
On Aug. 5, Moderna announced that the U.S. Food and Drug Administration (FDA) had approved mFLUSIVA, a flu vaccine. In clinical trials, mFLUSIVA proved more effective than marketed flu vaccines. It could help address an unmet need in this area. The current options aren't very good. Efficacy numbers range between 40% to 60% during the flu season, according to the U.S. Centers for Disease Control and Prevention.
Details
Source
Originally published at www.fool.com.